Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EPS (Basic) (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EPS (Basic) for 8 consecutive years, with -$0.69 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 87.41% year-over-year to -$0.69, compared with a TTM value of -$4.32 through Sep 2025, down 1828.0%, and an annual FY2024 reading of -$0.19, up 66.67% over the prior year.
  • EPS (Basic) was -$0.69 for Q3 2025 at X4 Pharmaceuticals, up from -$3.47 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $13.59 in Q2 2024 and bottomed at -$7.77 in Q1 2024.
  • Average EPS (Basic) over 5 years is -$0.54, with a median of -$0.6 recorded in 2022.
  • Peak annual rise in EPS (Basic) hit 4218.18% in 2024, while the deepest fall reached 54700.0% in 2024.
  • Year by year, EPS (Basic) stood at -$1.28 in 2021, then skyrocketed by 84.38% to -$0.2 in 2022, then soared by 55.0% to -$0.09 in 2023, then crashed by 122.22% to -$0.2 in 2024, then crashed by 245.0% to -$0.69 in 2025.
  • Business Quant data shows EPS (Basic) for XFOR at -$0.69 in Q3 2025, -$3.47 in Q2 2025, and $0.04 in Q1 2025.